Despite considerable medical progress, many diseases are still untreatable or inadequately treatable. The various therapies often have serious side effects that lead to a lasting reduction in the quality of life of those affected and to considerable costs for the healthcare system.
To this end, the "Early Clinical Trials " funding measure was launched on March 23, 2021. The aim is to promote science-initiated early clinical trials up to phase II in Germany. The aim is to develop and investigate innovative therapeutic approaches and new areas of application for known drugs that are highly relevant for the patients concerned and for the medical care of these people in Germany.
The following modules are eligible:
- Early clinical studies for a new application of already known drugs (repositioning or "repurposing")
- Early clinical trials for novel therapeutic approaches
Eligible to apply:
- State and state-recognized universities
- Non-university research institutions
- Companies in the commercial sector.
Funding period:
- Module 1: max. 3 years
- Module 2: max. 3 years of clinical development, plus 3 years of preclinical research
Three-stage procedure: Firstly, submission of the project outlines by June 15, 2021; secondly, after a positive evaluation of the outline, submission of the detailed project description is requested and finally, in the third step, the formal funding application is submitted, again after a positive vote.
Read more at: BMBF Funding Early Clinical Studies